(Total Views: 364)
Posted On: 06/05/2020 6:22:11 PM
Post# of 72
Hi xxxxx
As a follow-up to your email, attached is recent information as filed with the SEC, and a corresponding press release about our current plans for Gene Biotherapeutics and our lead product candidate Generx [Ad5FGF-4] that is being developed for the potential treatment of patients with refractory angina.
Regards,
Chris Reinhard
As a follow-up to your email, attached is recent information as filed with the SEC, and a corresponding press release about our current plans for Gene Biotherapeutics and our lead product candidate Generx [Ad5FGF-4] that is being developed for the potential treatment of patients with refractory angina.
Regards,
Chris Reinhard
(0)
(0)Scroll down for more posts ▼
